Biosign sells IBL Internet Business Logic Inc. Assets

TORONTO, Aug. 3, 2015 /CNW/ - Biosign Technologies Inc (TSXV: BIO) ("Biosign" or the "Company") announces that it has completed the sale of the business assets of wholly-owned subsidiary IBL Internet Business Logic Inc. to Quindell Services Inc. for a total purchase price of $2,500,000 which was paid in cash on closing. In conjunction with this transaction, all term loans plus interest payable by Biosign to Quindell Solutions Inc. have been forgiven to settle outstanding obligations amongst the parties.

About Biosign Technologies Inc (TSXV: BIO) Biosign is a developer of world class healthcare software solutions targeted at the Home Care and Allied Health Care markets. The Company's various software divisions, including ClinicServer™, EESI Corporate Benefits and AioMed GmbH offer industry-leading Home Healthcare and Allied Health clinic management solutions to international companies and service providers worldwide.

 Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Biosign Technologies Inc.